52 research outputs found
In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease
Both the replication of protein aggregates and their spreading throughout the brain are implicated in the progression of Alzheimer’s disease (AD). However, the rates of these processes are unknown and the identity of the rate-determining process in humans has therefore remained elusive. By bringing together chemical kinetics with measurements of tau seeds and aggregates across brain regions, we can quantify their replication rate in human brains. Notably, we obtain comparable rates in several different datasets, with five different methods of tau quantification, from postmortem seed amplification assays to tau PET studies in living individuals. Our results suggest that from Braak stage III onward, local replication, rather than spreading between brain regions, is the main process controlling the overall rate of accumulation of tau in neocortical regions. The number of seeds doubles only every ∼5 years. Thus, limiting local replication likely constitutes the most promising strategy to control tau accumulation during AD
In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease.
[Figure: see text].We acknowledge funding
from Sidney Sussex College Cambridge (GM) and the European Research Council Grant Number
669237 (to D.K.) and the Royal Society (to D.K.). The Cambridge Brain Bank is supported
by the NIHR Cambridge Biomedical Research Centre
Silkworm expression system as a platform technology in life science
Many recombinant proteins have been successfully produced in silkworm larvae or pupae and used for academic and industrial purposes. Several recombinant proteins produced by silkworms have already been commercialized. However, construction of a recombinant baculovirus containing a gene of interest requires tedious and troublesome steps and takes a long time (3–6 months). The recent development of a bacmid, Escherichia coli and Bombyx mori shuttle vector, has eliminated the conventional tedious procedures required to identify and isolate recombinant viruses. Several technical improvements, including a cysteine protease or chitinase deletion bacmid and chaperone-assisted expression and coexpression, have led to significantly increased protein yields and reduced costs for large-scale production. Terminal N-acetyl glucosamine and galactose residues were found in the N-glycan structures produced by silkworms, which are different from those generated by insect cells. Genomic elucidation of silkworm has opened a new chapter in utilization of silkworm. Transgenic silkworm technology provides a stable production of recombinant protein. Baculovirus surface display expression is one of the low-cost approaches toward silkworm larvae-derived recombinant subunit vaccines. The expression of pharmaceutically relevant proteins, including cell/viral surface proteins, membrane proteins, and guanine nucleotide-binding protein (G protein) coupled receptors, using silkworm larvae or cocoons has become very attractive. Silkworm biotechnology is an innovative and easy approach to achieve high protein expression levels and is a very promising platform technology in the field of life science. Like the “Silkroad,” we expect that the “Bioroad” from Asia to Europe will be established by the silkworm expression system
Recommended from our members
Super-resolution imaging unveils the self-replication of tau aggregates upon seeding.
Tau is a soluble protein interacting with tubulin to stabilize microtubules. However, under pathological conditions, it becomes hyperphosphorylated and aggregates, a process that can be induced by treating cells with exogenously added tau fibrils. Here, we employ single-molecule localization microscopy to resolve the aggregate species formed in early stages of seeded tau aggregation. We report that entry of sufficient tau assemblies into the cytosol induces the self-replication of small tau aggregates, with a doubling time of 5 h inside HEK cells and 1 day in murine primary neurons, which then grow into fibrils. Seeding occurs in the vicinity of the microtubule cytoskeleton, is accelerated by the proteasome, and results in release of small assemblies into the media. In the absence of seeding, cells still spontaneously form small aggregates at lower levels. Overall, our work provides a quantitative picture of the early stages of templated seeded tau aggregation in cells.This work was supported by
the UK Dementia Research Institute, which receives its funding from DRI Ltd., funded by the
UK Medical Research Council, Alzheimer’s Society, and Alzheimer’s Research. T.K. and
W.A.M. have received funding from the Innovative Medicines Initiative 2 Joint Undertaking
under grant agreement 116060 (IMPRiND). This Joint Undertaking receives support from the
European Union’s Horizon 2020 Research and Innovation Program and EFPIA. This work is
supported by the Swiss State Secretariat for Education, Research, and Innovation (SERI)
under contract 17.00038. WAM was funded by a Sir Henry Dale Fellowship jointly funded by
the Wellcome Trust and the Royal Society (Grant Number 206248/Z/17/Z) and by the Lister
Institute for Preventative Medicine. During this work E.D. was funded by a Deutsche
Forschungsgemeinschaft Research Fellowship (426806622) and an EMBO Fellowship (ALTF
173-2019). J.Y.L.L. is supported by the Croucher Foundation Limited (Hong Kong)
Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses
Soluble aggregates of the microtubule-associated protein tau have been challenging to assemble and characterize, despite their important role in the development of tauopathies. We found that sequential hyperphosphorylation by protein kinase A in conjugation with either glycogen synthase kinase 3β or stress activated protein kinase 4 enabled recombinant wild-type tau of isoform 0N4R to spontaneously polymerize into small amorphous aggregates in vitro. We employed tandem mass spectrometry to determine the phosphorylation sites, high-resolution native mass spectrometry to measure the degree of phosphorylation, and super-resolution microscopy and electron microscopy to characterize the morphology of aggregates formed. Functionally, compared with the unmodified aggregates, which require heparin induction to assemble, these self-assembled hyperphosphorylated tau aggregates more efficiently disrupt membrane bilayers and induce Toll-like receptor 4-dependent responses in human macrophages. Together, our results demonstrate that hyperphosphorylated tau aggregates are potentially damaging to cells, suggesting a mechanism for how hyperphosphorylation could drive neuroinflammation in tauopathies
Hyperphosphorylated tau self-assembles into amorphous aggregates eliciting TLR4-dependent responses.
Soluble aggregates of the microtubule-associated protein tau have been challenging to assemble and characterize, despite their important role in the development of tauopathies. We found that sequential hyperphosphorylation by protein kinase A in conjugation with either glycogen synthase kinase 3β or stress activated protein kinase 4 enabled recombinant wild-type tau of isoform 0N4R to spontaneously polymerize into small amorphous aggregates in vitro. We employed tandem mass spectrometry to determine the phosphorylation sites, high-resolution native mass spectrometry to measure the degree of phosphorylation, and super-resolution microscopy and electron microscopy to characterize the morphology of aggregates formed. Functionally, compared with the unmodified aggregates, which require heparin induction to assemble, these self-assembled hyperphosphorylated tau aggregates more efficiently disrupt membrane bilayers and induce Toll-like receptor 4-dependent responses in human macrophages. Together, our results demonstrate that hyperphosphorylated tau aggregates are potentially damaging to cells, suggesting a mechanism for how hyperphosphorylation could drive neuroinflammation in tauopathies.J.X.M. is supported by Dr. Herchel Smith Fellowship from Williams College .Y.Z. is supported by the Wellcome Trust Grant (107032AIA, R.A.F). and the Cambridge Cancer Center Pump Priming Grant and Royal Society University Research Fellowship to S.F.L. D.S. is supported by Clarendon Scholarship from Oxford University Press. A.M.H. is funded by Open Targets. G.B. Y.Y. are supported by the UK Dementia Research Institute that receives contributions from UK DRI Ltd, the UK MRC, the Alzheimer’s Society, and Alzheimer’s Research UK. C.E.B. is supported by a Wellcome Trust Investigator award (108045/Z/15/Z, C.E.B.). This work is supported by the UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK and by the Royal Society (RP150066, DK)
- …